Answers are grounded in this paper and cite their sources.
Human epidermal growth factor receptor 2 (HER2)-directed therapies, such as trastuzumab, can lead to hypersensitivity reactions (HSRs). Although they are uncommon, HSRs to such therapies are clinically significant, as they often can lead to treatment interruption or discontinuation. Even though there has been a longstanding use of trastuzumab and its biosimilars, there is still a paucity of data on the management of HSRs related to their use. In this case, a 31-year-old woman with anatomical stage II (pT2 pN0) right-sided HER2-positive breast cancer underwent mastectomy and axillary lymph node dissection on February 29, 2024. Since the patient was pregnant, initial care consisted of upfront surgery followed by doxorubicin, cyclophosphamide, and paclitaxel (AC-T), deviating from standard HER2-directed therapies due to their teratogenicity. She completed doxorubicin and cyclophosphamide (AC) for four cycles, followed by weekly paclitaxel (T) for 2 cycles. HER2-directed therapy with trastuzumab and pertuzumab (HP) was initiated immediately postpartum after delivery on September 20, 2024, and continued for a 1-year duration, whereas the remaining 2 cycles of paclitaxel were reinitiated after 3 weeks of postpartum recovery and ended on November 27, 2024. However, with her first HP cycle, the patient experienced a HSR with symptoms of angioedema, facial flushing, headache, and erythema. Despite adjustments to dosing rates, the adoption of weekly trastuzumab infusions, and the application of multiple pre-medications, recurrent HSRs to trastuzumab and alternative biosimilars continued. Inpatient desensitization was attempted multiple times, but it was the introduction of omalizumab every 2 weeks that eventually led to the prevention of HSRs onward. Weekly trastuzumab was returned from a 16-step infusion rate to 8-step to 4-step to a normal infusion rate over the course of several cycles, along with the de-escalation of adjunct pre-medications. She returned to full-rate treatment on March 14, 2025, then completed her last cycle of HP therapy on November 21, 2025. This case suggests the potential role of omalizumab as an adjunctive strategy for managing recurrent HSRs to trastuzumab, allowing patients to safely complete curative-intent HER2-targeted therapy.
No takes yet. Share an insight, caveat, or question.
Thakur et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: